Tiago Reis Marques, Pasithea Therapeutics CEO

Small-cap CNS out­fit inks API deal for pre­clin­i­cal MEK in­hibitor

Mi­a­mi-based pen­ny stock play­er Pa­sithea Ther­a­peu­tics is team­ing with CD­MO WuXi STA to make the ac­tive phar­ma­ceu­ti­cal in­gre­di­ent for its lead pre­clin­i­cal drug — com­plet­ing one of its last ma­jor re­quire­ments to sub­mit an IND to the FDA.

CEO Tia­go Reis Mar­ques tells End­points News that the deal, an­nounced Wednes­day, is for one kilo­gram of the ac­tive in­gre­di­ent for PAS-004, Pa­sithea’s lead drug, and that Pa­sithea hopes it will be enough API for both Phase I and Phase II tri­als.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.